Sample Page
Author:
R.J. Walker & Co.
Posted Date:
May 5, 2026
Banyan BioInnovations Launches as an Investment Firm to Support Clinical-Stage Drug Assets, Secures More Than $100M in Initial Commitments from Life Science Investors
R.J. Walker & Co.
May 5, 2026
Iterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual Meeting
R.J. Walker & Co.
May 4, 2026
Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
R.J. Walker & Co.
May 1, 2026
Brado AI Recognized for Advancing Interoperability Through HealthTech Ecosystem Pledge
R.J. Walker & Co.
April 21, 2026
Listo Announces Expanded Presence Across the U.S. with New Venues in 10 Additional States
R.J. Walker & Co.
April 15, 2026
Sonire Therapeutics Closes $18 Million Series A Financing to Advance Breakthrough HIFU Therapy for Pancreatic Cancer, Expands U.S. Clinical Development
R.J. Walker & Co.
April 15, 2026
Iterion Presents New Data on First-in-Class TBL1 Inhibitor Tegavivint, Targeting Wnt-Driven Cancers at AACR Annual Meeting
R.J. Walker & Co.
April 13, 2026
Brado AI Acquires ProviderIQ from Hatchleaf to Advance Precision Routing in Healthcare Access
R.J. Walker & Co.
April 13, 2026
Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed
R.J. Walker & Co.
March 25, 2026
Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory Osteosarcoma
R.J. Walker & Co.
February 12, 2026
1
2
Next
